Barclays Upgrades Vertex; Sees Stock Rising 12% to $150

An upgrade by Barclays on high hopes for a new cystic fibrosis drug wasn’t enough to send Vertex Pharmaceuticals (VRTX) higher in Monday market action. At a recent $134.37, the shares inched 0.37% higher after earlier climbing 1.5% in pre-market action. Earlier today, analyst Geoffrey Meachum lifted the drug maker to an “overweight” and raised his price […]